MNX1-AS1

Summary

MNX1-AS1 (MNX1 antisense RNA 1, HGNC:48954) is a long non-coding RNA gene on chromosome 7q36.3.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:48954
Approved symbol	MNX1-AS1
Name	MNX1 antisense RNA 1
Location	7q36.3
Locus type	RNA, long non-coding
Status	Approved
Aliases	CCAT5, LOC645249, MAYA
Ensembl gene	ENSG00000243479
Ensembl biotype	lncRNA
Entrez	645249
RNAcentral	URS000075D82B — lncRNA, 992 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 lncRNA

ENST00000480284, ENST00000818900, ENST00000818901

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000480284 — 2 exons

Exon	Start	End
ENSE00004223297	157010805	157011307
ENSE00004223298	157015889	157017621

Expression profiles

Bgee: expression breadth broad, 58 present calls, max score 87.44.

FANTOM5 (CAGE): breadth broad, TPM avg 0.7388 / max 19.5350, expressed in 288 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
205020	0.5861	269
82274	0.1527	96

Top tissues by expression

182 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.44	gold quality
body of pancreas	UBERON:0001150	71.25	gold quality
islet of Langerhans	UBERON:0000006	70.50	gold quality
pancreas	UBERON:0001264	70.17	gold quality
mucosa of transverse colon	UBERON:0004991	67.77	gold quality
body of stomach	UBERON:0001161	60.35	gold quality
rectum	UBERON:0001052	59.38	gold quality
stomach	UBERON:0000945	58.17	gold quality
transverse colon	UBERON:0001157	57.51	gold quality
ascending aorta	UBERON:0001496	56.85	gold quality
hindlimb stylopod muscle	UBERON:0004252	56.37	silver quality
small intestine Peyer’s patch	UBERON:0003454	55.09	gold quality
fundus of stomach	UBERON:0001160	54.81	gold quality
small intestine	UBERON:0002108	54.28	gold quality
intestine	UBERON:0000160	52.70	gold quality
colon	UBERON:0001155	52.69	gold quality
muscle layer of sigmoid colon	UBERON:0035805	52.38	gold quality
adenohypophysis	UBERON:0002196	52.24	gold quality
large intestine	UBERON:0000059	52.12	gold quality
left testis	UBERON:0004533	50.86	gold quality
right testis	UBERON:0004534	50.83	gold quality
testis	UBERON:0000473	49.61	gold quality
pituitary gland	UBERON:0000007	49.60	gold quality
duodenum	UBERON:0002114	48.69	gold quality
muscle of leg	UBERON:0001383	48.29	silver quality
vermiform appendix	UBERON:0001154	48.03	gold quality
gall bladder	UBERON:0002110	47.27	gold quality
anatomical system	UBERON:0000467	46.20	gold quality
aorta	UBERON:0000947	45.99	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	45.99	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.43

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 18)

• FIGO stage, distant metastasis, and MNX1-AS1 expression were independent prognostic factors of both overall survival and progression-free survival for patients with epithelial ovarian cancer. (PMID:29271994)
• MNX1-AS1 promoted proliferation and inhibited apoptosis of cervical cancer cells through MAPK pathway. Expression of MNX1-AS1 is upregulated in cervical cancer tissues and cell lines and correlate with poor prognosis. (PMID:30302806)
• Data concluded that E2F1-mediated MNX1-AS1-miR-218-5p-SEC61A1 feedback loop contributed to the progression of colon adenocarcinoma. (PMID:30362161)
• This study found a novel signaling pathway, namely MNX1-AS1/miR-527/BRF2 axis, involved in lung cancer progression. (PMID:30618167)
• MNX1-AS1 promoted COMMD8 expression through sponging miR-218-5p. MNX1-AS1 promoted hepatocellular carcinoma progression through activating COMMD8. (PMID:30982576)
• Long noncoding RNA MNX1-AS1/miR-34a/SIRT1 regulatory axis could play an important role in esophageal squamous cell carcinoma progression. (PMID:31170665)
• TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2. (PMID:31924214)
• LncRNA MNX1-AS1 promotes progression of intrahepatic cholangiocarcinoma through the MNX1/Hippo axis. (PMID:33093444)
• Clinical significance of long noncoding RNA MNX1-AS1 in human cancers: a meta-analysis of cohort studies and bioinformatics analysis based on TCGA datasets. (PMID:33685348)
• MYC-Activated LncRNA MNX1-AS1 Promotes the Progression of Colorectal Cancer by Stabilizing YB1. (PMID:33782099)
• LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis. (PMID:34789303)
• Actinidia chinensis Planch Root extract suppresses the growth and metastasis of hypopharyngeal carcinoma by inhibiting E2F Transcription Factor 1-mediated MNX1 antisense RNA 1. (PMID:35152841)
• LncRNA MNX1-AS1: A novel oncogenic propellant in cancers. (PMID:35290890)
• Comprehensive network analysis of dysregulated genes revealed MNX1-AS1/hsa-miR-4697-3p/HOXB13 axis in ovarian cancer chemotherapy response. (PMID:35639251)
• Activation of MYO1G by lncRNA MNX1-AS1 Drives the Progression in Lung Cancer. (PMID:35819746)
• LncRNA MNX1-AS1 sustains inactivation of Hippo pathway through a positive feedback loop with USP16/IGF2BP3 axis in gallbladder cancer. (PMID:35953000)
• MNX1-AS1, a c-Myc induced lncRNA, promotes the Warburg effect by regulating PKM2 nuclear translocation. (PMID:36476366)
• LncRNA-CCAT5-mediated crosstalk between Wnt/beta-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity. (PMID:38010289)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.